How doctors choose an ADHD medication for adults

Two adults with the same diagnosis can leave their appointments with different prescriptions, and both choices can be sound. The choice depends on the person, not only on the diagnosis. This article explains the factors prescribers weigh, drawn from FDA labels, NICE guideline NG87 and a 2024 American Family Physician review. Knowing the factors helps you bring the right information to the visit. It is not a guide to choosing your own medication.

As of October 19, 2026, the United States had no published adult ADHD guideline: APSARD's guidelines page announced a final review stage in August 2026 but listed no published document. That is why the guidance below leans on England's NICE guideline alongside US sources. See clinical guidelines for adult ADHD.

1. Confirming the starting point

NICE says that before medication starts, a person should have a full assessment that includes a review confirming they still meet the criteria for ADHD and need treatment. That is one reason a prescriber may want an evaluation, or records of an earlier one, before writing a first prescription. Under New Jersey's rule for controlled substances, N.J.A.C. 13:35-7.6(b), a practitioner must take a thorough history, perform an examination appropriate to the standard of care, make a reasonable effort to obtain and review the patient's records, check the Prescription Monitoring Program and write a treatment plan before starting one.

2. Physical health and the heart

The NICE pre-treatment review covers medical history (looking for conditions that rule out specific medicines), current medication, weight, baseline pulse and blood pressure, and a cardiovascular assessment. NICE recommends a cardiology opinion first if certain features are present, including:

• congenital heart disease or previous heart surgery
• sudden death in a first-degree relative under 40 suggesting heart disease
• fainting on exertion, or chest pain or palpitations suggesting a heart cause
• blood pressure in the hypertensive range for adults

NICE says an ECG is not needed before starting stimulants, atomoxetine or guanfacine unless one of those features applies or another treated condition carries extra cardiac risk. The stimulant labels advise avoiding use in people with known structural heart abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease or other serious heart disease, and monitoring blood pressure and pulse. The atomoxetine label calls for a careful history and physical exam for heart disease before treatment. More is in ADHD medication, heart health and blood pressure.

3. Mental health and co-occurring conditions

• Mood and bipolar risk: stimulant labels tell prescribers to screen for risk factors for a manic episode before starting, such as depressive symptoms or a family history of suicide, bipolar disorder or depression. The atomoxetine label asks for screening for a personal or family history of mania and depression. NICE says to stop ADHD medication during an acute psychotic or manic episode. See ADHD or bipolar disorder?
• Anxiety, tics and autism: NICE says to offer people with these conditions the same medication choices as other people with ADHD, with slower dose changes and closer monitoring when other conditions are present. The American Family Physician review lists atomoxetine, viloxazine and bupropion among options for adults with concurrent anxiety or depression.
• Substance use: NICE includes a risk assessment for substance misuse and drug diversion in every pre-treatment review. See ADHD and substance use.

4. Other medications and conditions

A complete medication list changes choices more often than people expect. Stimulants, atomoxetine and viloxazine are all contraindicated with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping one. Amphetamine labels warn of a higher risk of serotonin syndrome when combined with serotonergic drugs such as SSRIs, SNRIs and triptans, and the Concerta label lists serotonin syndrome with serotonergic drugs among reported reactions. The atomoxetine label lists narrow angle glaucoma and pheochromocytoma as contraindications and notes larger heart-rate increases in people who are CYP2D6 poor metabolizers. Viloxazine is contraindicated with sensitive CYP1A2 substrates. Bring every prescription, over-the-counter product and supplement you take. The interactions page, ADHD medication drug interactions, goes further.

Pregnancy, plans for pregnancy and breastfeeding also matter. Each label has a pregnancy and lactation section, and the Concerta label notes a pregnancy exposure registry. The NIH LactMed database summarizes published data on medicines during breastfeeding. See ADHD in pregnancy and postpartum.

5. Your day: when symptoms matter most

Release design decides when a medication works across the day, and this is where your schedule matters. NICE suggests that prescribers think about once-daily modified-release stimulants for convenience, better adherence, less stigma because no dose is needed at work, and lower risk of misuse and diversion than with immediate-release forms. It adds that immediate-release forms may suit people who need more flexible timing. Some products are designed around specific routines: Jornay PM is taken only in the evening, and the Xelstrym patch is applied 2 hours before an effect is needed and removed within 9 hours. Tell your prescriber about early starts, late shifts, evening study and driving. Extended-release ADHD medications explained describes the designs.

6. Misuse and diversion risk

The stimulant boxed warning, required across the class by the FDA in 2023, tells prescribers to assess each patient's risk of abuse, misuse and addiction before prescribing and to reassess it during treatment. NICE advises caution where there is a risk of diversion for cognitive enhancement or appetite suppression, and says not to offer immediate-release stimulants, or modified-release ones that can easily be injected or snorted, when misuse or diversion is a risk. The American Family Physician review suggests controlled substance agreements and prescription drug monitoring programs. These checks are standard practice, not a judgment about you. New York's own prescription monitoring check is explained in I-STOP and ADHD prescriptions.

7. Coverage, generics and supply

A medication only helps if you can fill it. Formularies differ by plan, some products have generics and some do not, and as of October 2026 the FDA drug shortage database still listed mixed amphetamine salts immediate-release tablets, lisdexamfetamine and methylphenidate extended-release tablets as current shortages. A prescriber may ask which pharmacy you use and what your plan covers before choosing. See generic ADHD medications and the cost guides for New York and New Jersey.

8. Your history with medication

What you have taken before, and how it went, is some of the most useful information you can bring. NICE describes switching between lisdexamfetamine and methylphenidate after a 6-week trial that did not give enough benefit, and considering atomoxetine if both are not tolerated or not effective. It recommends a second opinion or a tertiary service if symptoms have not responded to one or more stimulants and one nonstimulant. Bring old prescription records or pharmacy printouts if you have them.

What to bring to the appointment

• A list of every medication, supplement and over-the-counter product you take
• Any personal or family history of heart disease, sudden death, fainting or high blood pressure
• Any personal or family history of bipolar disorder, depression, psychosis or substance use
• Past ADHD medications, how long you took them and why you stopped
• Your daily schedule, and when focus matters most
• Pregnancy plans or breastfeeding, and your insurance plan and pharmacy

Dr. Shershow, a psychiatrist licensed in New York and New Jersey, reviews these factors in an adult ADHD evaluation, which ends with the findings and the treatment options that fit. For a broader comparison of the two main groups, see stimulant vs nonstimulant ADHD medication.